Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: A.R.Venkatesh who wrote (4163)	2/4/1999 8:11:00 AM
From: Jonathan Schonsheck	Respond to of 4342

I quite agree; following is a Press Release from last summer which bears on the HIV+ treatment. Note: patents granted. But remember too that there is a fourth initiative: on-line selling of natural products, "New Century Nutrition." I do not know just where or how they will be marketed, but we have 1,000,000 pills of Andrographalite in cold storage. Jonathan Paracelsian Patents Approved for HIV Treatment and Cancer Screen July 21, 1998, Ithaca, New York (Nasdaq: PRLN). Paracelsian, Inc. (http://www.paracelsian.com) has received notice of allowance for two of its most important and potentially profitable patent applications. "The approval of these patent applications, the first relating to a new method for treating HIV and the second relating to a new screen for Cancer, is a major step in realizing our corporate strategy to fully develop all of our intellectual assets," said Bernie Landes, Paracelsian's Chairman, President and CEO. "We fully intend to optimize the market potential for both of these breakthrough technologies and have initiated an aggressive search for the best possible partners to assist us in achieving our goal," he added. In the first approved application, the company was granted claims for a novel method of treating HIV infection. The method works through a unique pathway involved in the progression of HIV. AIDS is characterized by a compromised immune system resulting from the systemic depletion of "T cells" called CD4+ T lymphocytes and unresponsiveness of the remaining T cells. The level of T cells serves as a diagnostic indicator of the progression of the disease. HIV infected T cells are known to be directly toxic or "cytopathic" to other CD4+ T lymphocytes through the initiation of specific process associated with rapid loss of CD4+ T cells and disease progression. This process is a key mechanism of T cell depletion during progressive HIV infection. Paracelsian expects that the new method will be used beneficially in conjunction with other AIDS treatments, including reverse transcriptase and protease inhibitors currently being successfully used as part of "drug cocktails". Paracelsian scientists previously discovered a cell cycle pathway that can be used for drug screening and received a patent on this technology. The company is currently screening it library of 2,764 Traditional Chinese Medicine extracts, along with other novel herbs and botanicals it has recently acquired, in search of compounds that will inhibit HIV progression. Paracelsian, Inc. is currently seeking partners to pursue FDA approvals and market the novel treatment. The second patent application includes claims for assays that evaluate the carcinogenicity (cancer causing activity) of potential carcinogens or mutagens by monitoring the levels of markers of cellular hyper-proliferation called "cyclin dependent kinases", or "CDK's" Paracelsian's team of scientists discovered that there is a consistent relationship between cyclin dependent kinase concentrations and cell growth and proliferation. Because cell hyper-proliferation is the most fundamental property of cancer, Paracelsian's technology has broad application to detecting and monitoring cancer cells as they are growing and proliferating. The patent application that was allowed relates to using this technology to quantifying carcinogenicity of test substances, even substances which have been previously thought to be non-genotoxic and/or non-mutagenic. Paracelsian's patented CDK assays measure the concentration of at least one cyclin dependent kinase in the blood, plasma or serum of an animal or human, and correlates that concentration to the presence of abnormal cellular proliferation or tumor development in any tissue of the organism from which the sample was obtained. These assay systems offer potential users the ability not only to screen sample compounds for their potential mutagenic/carcinogenic/neoplastic properties, but also to screen for compounds which prevent this activity as well. Paracelsian's scientists have been using these assays for drug screening for cancer treatments. Using this assay, Paracelsian's scientists have identified several compounds from the company's library of Traditional Chinese Medicine extracts that have shown high levels of anti-cancer activity. A group of the most highly active compounds are now being evaluated for anti-cancer activity in human tumor models of breast and prostate cancer as part of a collaborative research agreement Paracelsian recently announced with the Southern Research Institute, one of the nation's leading cancer research centers. Paracelsian has additional foreign and U.S. Patent applications pending that are related to both of these technologies. The company has also filed additional foreign and U.S. applications that are related to this technology. The company is actively seeking partners to fully develop the market potential of these patents by pursuing FDA approvals and by marketing the novel treatments that it has discovered.

To: A.R.Venkatesh who wrote (4163)	2/4/1999 8:29:00 AM
From: John H. Farro	Read Replies (2) \| Respond to of 4342

A.R. I also bought some more PRLN recently. I've been in and out of this company since 1993 and I think I would have been a rich man by now had we had competent management since the beginning. I lost a ton of money under old management before selling all of my stock--I think it was in April 1997 that I sold. I had become convinced at that point that PRLN's management was so incompetent that they would probably not be able to pull off the AndroVir launch. I didn't realize at that point that management was corrupt as well as incompetent. I bought 10 shares in early July so I would be able to go to the stockholders meeting and question Rhodes. To say that I was not impressed by what I saw is an understatement. I've reinvested fairly heavily since new management came in--my most recent purchase being at 1 5/32 after the Ah Immunoassay announcemnt. There is still no guarantee that the company will ultimately be successful, but things are looking much more promising than they were even a few months ago. As far as your predictions for three great news releases: 1) I am 100% sure that the major BioFIT promotion will occur. 2) I am 90 - 95% sure that they will get a contract signed for the Ah Immunoassay. 3) I would not be at all surprised about a partnership with a major pharma to develop a compound that could fight multi-drug resistant HIV virus. I am far less sure about the timing of this event. I think it is highly likely to occur at some time in the future, but I don't know if it will happen this spring. If someone stuck a gun to my head and forced me to guess, I would guess there is a 40 - 50% that we will see this announcement this spring. I really hope you are right in your prediction, A.R. Robin